If approved, Forxiga has the potential to change the treatment paradigm for millions of people in the EU suffering from chronic kidney disease... Jun 28
Farxiga could become the first SGLT2 inhibitor approved to treat patients with chronic kidney disease, with and without type-2 diabetes... Jan 06
For roxadustat, more than 40 abstracts present safety and efficacy outcomes in anaemia of chronic kidney disease ... Oct 20
-Advertisements-